Supplementary Table 3. Multivariable Analysis of Predictors of Clinical POR in Patients Who Were Treated with Anti-TNF to Prevent Early Endoscopic POR in Crohn's Disease

Factor	HR (95% CI)	P-value
Female sex	1.809 (0.754–4.339)	0.184
Active smoker	1.566 (0.459–5.351)	0.474
Perianal lesions	0.847 (0.375–1.916)	0.691
Prior bowel resection	1.260 (0.539–2.945)	0.593
Exposure to anti-TNF before surgery	0.925 (0.179–4.783)	0.926
Primary nonresponder to 1 anti-TNF before surgery	1.451 (0.563–3.739)	0.441
Concomitant immunosuppressive drug	0.737 (0.330–1.644)	0.456
Fistulizing phenotyp (B3)	0.520 (0.220–1.228)	0.136
Optimizing anti-TNF+addition of immunosuppressive drug	7.383 (1.544–35.309)	0.012
Rutgeerts index ≥i3	3.115 (1.166–8.319)	0.023

POR, postoperative recurrence; TNF, tumor necrosis factor; HR, hazard ratio; CI, confidence interval.